Reproductive Safety Issues in MS with New Therapies: Presented by Emmanuelle Waubant, MD, PhD

Infectious Complications of Immunotherapies for MS: Presented by Avindra Nath, MD

Fingolimod inhibits cytotoxic T cells: A novel immunomodulatory effect of the unphosphorylated compound
Achilles Ntranos, MD, Johns Hopkins School of Medicine; Inna V Grishkan, BS, Johns Hopkins School of Medicine; Dionne P Robinson, BS, Johns Hopkins Bloomberg School of Public Health; Olivia J Hall, MSc, Johns Hopkins Bloomberg School of Public Health; Sabra L Klein, PhD, Johns Hopkins Bloomberg School of Public Health; Peter A Calabresi, MD, FAAN, Johns Hopkins School of Medicine; Anne R Gocke, PhD, Johns Hopkins School of Medicine

Long-Term Safety Of Fingolimod: Updated Integrated Safety Analyses
Jeffrey A Cohen, MD, Cleveland Clinic, Cleveland, OH, USA; Paul O'Connor, MD, University of Toronto; Lixin Zhang-Auberson, MD, Novartis Pharma AG; Astrid Keil, MD, Novartis Pharma AG; William Collins, MD, Novartis Pharma AG; Nikolaos Sfikas, PhD, Novartis Pharma AG; Philipp von Rosenstiel, MD, Novartis Pharma AG

Discussion/Q&A/Closing Remarks